Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Study ID
NCT02795429

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Completed

Trial Acronym

Trial Summary

The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered intravenously (i.v.) as a single agent or in combination with capmatinib administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

More informations

Trial Starting Date

Jun 15,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit